Phase I Platinum Based Chemotherapy Plus Indomethacin

Inclusion Criteria: * Subjects with a histological proven malignancy receiving cisplatin combined with gemcitabine or 5FU/capecitabine. (cisplatin dose range 60-80 mg/m2) (Arm I) or CAPOX (oxaliplatin, capecitabine) (Arm II) in a 21 day cycle. * Age ≥ 18 years * Platinum-based chemotherapy naïve for at least 6 months. * Subjects with at least one evaluable lesion. * WHO Performance Status of 0 or 1. * Female participants should be of non-child bearing potential either physiologic or by using adequate contraception, have a negative serum pregnancy test, and refrain from breast feeding. * Written informed consent. Exclusion Criteria: * Known or suspected allergy or hypersensitivity to indomethacin or any agent given in association with this trial, in particular subjects who have a history of severe hypersensitivity reactions to anti-emetics (5-HT3 antagonists, metoclopramide or corticosteroids) and acetylsalicylic acid or other prostaglandin synthetase inhibitors. * Symptomatic brain or meningeal tumors * Subjects with seizure disorder requiring medication (such as corticosteroids or anti-epileptics). * Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study: * Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen * Unstable angina pectoris * Symptomatic congestive heart failure NYHA class ≥ 3 (see appendix 13.6) * Myocardial infa…